162 related articles for article (PubMed ID: 27124410)
1. Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.
Miquel-Cases A; Retèl VP; Lederer B; von Minckwitz G; Steuten LM; van Harten WH
PLoS One; 2016; 11(4):e0154386. PubMed ID: 27124410
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands.
Miquel-Cases A; Steuten LM; Rigter LS; van Harten WH
BMC Cancer; 2016 Sep; 16(1):712. PubMed ID: 27595620
[TBL] [Abstract][Full Text] [Related]
3. Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.
Cole AL; Barber EL; Gogate A; Tran AQ; Wheeler SB
Int J Gynecol Cancer; 2018 Jul; 28(6):1077-1084. PubMed ID: 29683880
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide.
Liubao P; Xiaomin W; Chongqing T; Karnon J; Gannong C; Jianhe L; Wei C; Xia L; Junhua C
Pharmacoeconomics; 2009; 27(10):873-86. PubMed ID: 19803541
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
10. A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.
Thavorn K; Coyle D; Hoch JS; Vandermeer L; Mazzarello S; Wang Z; Dranitsaris G; Fergusson D; Clemons M
Support Care Cancer; 2017 Aug; 25(8):2505-2513. PubMed ID: 28281050
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
13. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
van Kampen RJW; Ramaekers BLT; Lobbezoo DJA; de Boer M; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FPJ; van Riel JMG; Peters NAJB; Tjan-Heijnen VCG; Joore MA
Eur J Cancer; 2017 Jul; 79():238-246. PubMed ID: 28245951
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
[TBL] [Abstract][Full Text] [Related]
17. Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.
Miquel-Cases A; Steuten LM; Retèl VP; van Harten WH
Breast; 2015 Aug; 24(4):397-405. PubMed ID: 25937263
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of docetaxel for breast cancer.
Lwin Z; Leighl N
Expert Opin Pharmacother; 2009 Feb; 10(2):283-90. PubMed ID: 19236199
[TBL] [Abstract][Full Text] [Related]
19. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC).
Lee SG; Jee YG; Chung HC; Kim SB; Ro J; Im YH; Im SA; Seo JH
Breast Cancer Res Treat; 2009 Apr; 114(3):589-95. PubMed ID: 18437555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
